RVNC Stock Summary and Trading Ideas (Revance Therapeutics | NASDAQ:RVNC)

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Revance Therapeutics trades on the NASDAQ stock market under the symbol RVNC.

As of January 17, 2025, RVNC stock price climbed to $3.68 with 8,156,028 million shares trading.

RVNC has a market cap of $386.04 million. This is considered a Small Cap stock.

Last quarter Revance Therapeutics reported $60 million in Revenue and -$.37 earnings per share. This fell short of revenue expectation by $-8 million and exceeded earnings estimates by $.01.

In the last 3 years, RVNC traded as high as $37.98 and as low as $2.30.

The top ETF exchange traded funds that RVNC belongs to (by Net Assets): IWM, VTI, VXF, IWO, IBB.

RVNC has underperformed the market in the last year with a return of -39.3%, while the SPY ETF gained +28.0%. In the last 3 month period, RVNC fell short of the market, returning -29.0%, while SPY returned +3.0%. However, in the most recent 2 weeks RVNC has outperformed the stock market by returning +19.1%, while SPY returned +1.0%.

RVNC support price is $3.16 and resistance is $3.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RVNC shares will trade within this expected range on the day.